Usefulness of the SF-36 Health Survey in screening for depressive and anxiety disorders in rheumatoid arthritis

Table 3 Pearson’s correlation analysis of bivariate associations

	Depression	Anxiety	MH	MCS
Depression	–
Anxiety	0.59***	–
MH	−0.71***	−0.70***	–
MCS	−0.66***	−0.63***	0.91***	–
Age	−0.07	−0.23*	−0.29**	−0.32**
Disease duration	0.04	0.04	0.07	0.06
Fatigue	0.35***	0.32**	0.39***	0.39***
Pain	0.38***	0.31**	0.36***	0.30**
HAQ	0.57***	0.35**	0.46***	0.37**
TJC	0.27*	0.23*	0.29**	0.31**
SJC	0.01	0.05	0.01	0.08
ESR	0.28**	0.10	0.17	0.18
PGA	0.26*	0.27*	0.27*	0.25*
DAS28	0.35**	0.31**	0.32**	0.31**
SF-36
PF	−0.48***	−0.36**	0.41***	0.34**
RP	−0.48***	−0.30**	0.46***	0.51***
BP	−0.47***	−0.31**	0.39***	0.41***
GH	−0.34***	−0.48***	0.58***	0.60***
VI	−0.49***	−0.40***	0.60***	0.72***
RE	−0.49***	−0.42***	0.63***	0.82***
SF	−0.63***	−0.48***	0.58***	0.67***
PCS	−0.42***	−0.28**	0.25*	0.24*

MH SF-36 mental health subscale, MCS SF-36 mental component summary, HAQ health assessment questionnaire, TJC Tender Joint count, SJC swollen joint count, ESR erythrocyte sedimentation rate, PGA patient global assessment, DAS28 28-joint disease activity score, CRP C-reactive protein, BMI body mass index, SF-36 short form 36, PF physical function, RP role physical, BP bodily pain, GH global health, VI vitality, RE role emotional, SF social functioning, PCS SF-36 physical component summary. Depression measured via PHQ2 (score range 0–6). Anxiety measured via GAD2 (score range 0–6)
*p < 0.05. **p < 0.01. ***p < 0.001

ISSN: 1471-2474